Should you consider putting your money into the iShares U.S. Pharmaceuticals ETF (IHE)?

Overview of iShares U.S. Pharmaceuticals ETF (IHE)

The iShares U.S. Pharmaceuticals ETF (IHE) offers investors comprehensive access to the pharmaceutical sector within the equity market. This fund, managed passively and introduced on May 1, 2006, is designed to track the performance of pharmaceutical companies.

Advantages of Passive ETFs

Passive ETFs have become increasingly favored by both individual and institutional investors due to their cost-effectiveness, transparency, flexibility, and tax benefits. These features make them particularly appealing for those with a long-term investment horizon.

Sector Diversification

Sector-focused ETFs allow investors to gain exposure to a wide range of companies within a specific industry, reducing risk and enhancing diversification. The Healthcare - Pharma sector is one of sixteen major categories in the Zacks Industry classification, currently ranked ninth and positioned in the lower 44% of sectors.

Fund and Index Information

Blackrock sponsors the IHE ETF, which has accumulated over $1.02 billion in assets, making it a significant player in the pharmaceutical sector. The fund aims to replicate the performance of the Dow Jones U.S. Select Pharmaceuticals Index, before accounting for fees and expenses. This index is weighted by market capitalization and includes companies that manufacture prescription and over-the-counter medications and vaccines, but excludes vitamin producers.

Expense Ratio and Yield

When comparing ETFs, the expense ratio is a key consideration, as lower fees can lead to better returns if other factors are equal. IHE has an annual operating expense of 0.38%, positioning it among the more affordable options in its category. The fund also offers a trailing 12-month dividend yield of 1.71%.

Portfolio Allocation and Leading Holdings

Although ETFs provide diversification, reviewing the specific holdings is essential before investing. Most ETFs, including IHE, are highly transparent, revealing their holdings daily. IHE's portfolio is almost entirely allocated to the Healthcare sector. Johnson & Johnson (JNJ) represents approximately 23.92% of the fund's assets, with Eli Lilly (LLY) and Merck & Co Inc (MRK) following. The top ten holdings make up about 79% of the total assets managed by the fund.

Performance and Risk Profile

Year-to-date, IHE has delivered a return of around 3.35%, and over the past year (as of March 9, 2026), it has gained roughly 23.29%. During the last 52 weeks, the ETF's price ranged from $61 to $91.84. With a beta of 0.50 and a three-year standard deviation of 15.84%, the fund is considered relatively high risk. However, its 59 holdings help mitigate risks associated with individual companies.

Alternative Pharmaceutical ETFs

IHE holds a Zacks ETF Rank of 2 (Buy), based on factors such as expected returns, expense ratio, and momentum. This makes it a strong choice for those seeking exposure to healthcare ETFs.

Conclusion

For more information on this ETF and others, use screening tools to find products that align with your investment goals and stay updated with articles covering the latest trends in ETF investing.